GUARD-AF is an example of the commitment of the BMS, Pfizer Alliance in trying to further the standard of care in patients with atrial fibrillation, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
GUARD-AF is an example of the commitment of the BMS, Pfizer Alliance in trying to further the standard of care in patients with atrial fibrillation, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
Transcript
What must physicians and patients understand about risk of atrial fibrillation? How can earlier detection improve patient care for this condition?
Atrial fibrillation is a condition with very high unmet need. It's important that physicians, healthcare providers, and patients and their families are aware of this unmet need. Atrial fibrillation affects about 8 million people in the US. Atrial Fibrillation itself increases the risk of stroke about 5-fall—many people aren't aware that they have atrial fibrillation. So, trying to detect atrial fibrillation early is important, because if you can detect it early then you can try to prevent the incidence of stroke or the occurrence of stroke, and stroke can be a highly devastating condition for not only patients but families, caregivers. So, to try to avoid the event by screening for atrial fibrillation is a goal and something that GUARD-AF will help us understand better.
How can increasing data within practiced atrial fibrillation detection improve the gap in knowledge by national screening committees and guideline-making bodies?
The GUARD-AF study is a study that will answer a question for which there's no data right now: Does screening for atrial fibrillation actually reduce the risk of stroke? This has been called out as a gap in knowledge by national screening and guideline committees, including the United States Preventive Services Task Force. So, GUARD-AF will help to answer that question for these committees; but just as importantly, GUARD-AF will help to answer this question for healthcare providers and patients who really need to know this kind of information to try to avoid the consequences of serious events such as stroke. GUARD-AF is an example of the commitment of the BMS, Pfizer Alliance in trying to further the standard of care in patients with atrial fibrillation.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More